<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02786745</url>
  </required_header>
  <id_info>
    <org_study_id>225678-007</org_study_id>
    <nct_id>NCT02786745</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris</brief_title>
  <official_title>A Safety and Efficacy Study to Compare Dapsone Dermal Gel With Vehicle Control in Patients With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedDerm Associates</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedDerm Associates</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To find out the safety and effectiveness of dapsone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to find out more about the safety and effectiveness of an
      investigational drug called Dapsone gel for patients with acne vulgaris.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Acne Assessment Score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Acne severity (Lesion count) will be evaluated on the face by the investigator using a 5-point Global Acne Assessment Score.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>Dapsone gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapsone gel applied topically to the face once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle control applied once daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapsone gel</intervention_name>
    <description>Dapsone gel applied to face once daily for 12 weeks</description>
    <arm_group_label>Dapsone gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo applied to face once daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adolescent or adult male and female patients who are 12 years of age or older.

          -  Acne vulgaris patients with minimum of 20 but not more than 50 inflammatory lesions on
             the face; a minimum of 30 but not more than 100 noninflammatory lesions.

          -  Patients with an acne grade of 3(moderate)

          -  A negative uring pregnancy test result for females of childbearing potential at the
             screening and day 1 visits.

          -  Patient is in good health as determined by medical history, physical examination, and
             vital signs.

          -  Patient is willing to avoid excessive or prolonged exposure of the treated skin to
             ultraviolet throughout the study.

          -  Patient is willing to follow study instructions, complete study assessments without
             any assistance, and likely to complete all required visits.

        Exclusion Criteria:

          -  Uncontrolled systemic disease(s).

          -  Severe cystic acne, acne conglobata, acne fulminans, or secondary acne.

          -  One or more nodule(s) or cyst(s) above the mandibular line.

          -  Using systemic immunosuppressive drugs within 4 weeks prior to screening or
             anticipated use of any systemic therapy with the potential to affect acne during the
             study.

          -  Any of the following topical procedures or treatments on the face occurring in the
             specified period prior to baseline(day 1).&quot;

               -  1 week: phototherapy devices, energy-based devices, adhesive cleansing strips, or
                  cosmetic procedures.

               -  2 weeks: anti-inflammatory drugs, salicylic acid, coricosteroids, antibiotics,
                  antibacterials, retinoids, other topical acne treatments.

          -  Any of the following systemic medications taken in the specified period prior to
             baseline(day 1):

               -  2 weeks: anti-inflammatory drugs

               -  4 weeks: antibiotics

               -  6 months: other acne treatments

          -  Skin abnormalities (other than acne vulgaris), excessive hair, or other physical
             characteristics in or around the test sites that could confound the study

          -  Patients who have any allergy or sensitivity to the study drugs or its components

          -  Females who are pregnant, nursing, or planning a pregnancy during the study or think
             they may be pregnant at the start of the study

          -  Current enrollment in an investigational drug or device study, or participation in
             such a study whithin 30 days prior to screening for this study

          -  Taking oral dapsone or antimalarial medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MedDerm Associates</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2014</study_first_submitted>
  <study_first_submitted_qc>May 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2016</study_first_posted>
  <last_update_submitted>May 25, 2016</last_update_submitted>
  <last_update_submitted_qc>May 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>MedDerm Associates</investigator_affiliation>
    <investigator_full_name>Michelle Pelle, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapsone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

